timothy sykes logo

Stock News

Will Cidara’s CD388 Revolutionize Flu Treatment?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 9/24/2025, 5:03 pm ET 9/24/2025, 5:03 pm ET | 5 min 5 min read
Will Cidara’s CD388 Revolutionize Flu Treatment? Thumbnail

Cidara Therapeutics Inc.’s stock surged 20.79% after promising trial results and FDA designation fueled investor optimism.

Candlestick Chart

Live Update At 17:03:05 EST: On Wednesday, September 24, 2025 Cidara Therapeutics Inc. stock [NASDAQ: CDTX] is trending up by 20.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Metrics and Current Insights

As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Every successful trading strategy hinges on risk management and the protection of one’s capital. While it is easy to become fixated on winning each trade, the reality is that losses are inevitable. What’s crucial is that traders adopt strategies that safeguard their initial investments. By maintaining focus on sustainable progress rather than short-term victories, traders enhance their chances of long-term success in the market.

As we venture into analyzing the recent developments, it’s essential to glance through Cidara Therapeutics’ financial landscape. With admirable foresight, the company has been optimizing its resources for research and development, reflecting keenly on critical metrics. Despite the challenging financial parameters such as a negative net income of about $25M, the leap in Stock-Based Compensation, which, holds notable weight in growth very similar to the laws of nature, seeks equilibrium through this transformation.

Moreover, their operating cash flow, while in the negative territory at roughly -$41M, signifies the intense reinvestment Cidara is committed to, propelling its innovation forward. It’s also noteworthy that Cidara’s enterprise value nears $1.36B, highlighting investor sentiment poised on the potential harvest yet to bloom.

Anticipated Impact of News on CDTX

The intrigue surrounding CD388 is not without reason. WBB Securities’ reaffirmation of Cidara’s upward stock potential entwined with the CD388’s breakthrough narratives may potentially sculpt the trajectory of Cidara’s stock in a market where innovation dictates the hierarchy. The announcement of both positive efficacy and safety data concerning CD388 adds a significant feather to its cap, encouraging a favorable market response.

More Breaking News

Breaking down their interaction, the two anticipated presentations at the ISRV meeting aim to illuminate CD388’s prowess further, offering grounds for renewed optimism. These presentations are poised to act as catalysts for more investor confidence and potentially lift stock valuation.

Eyes on the Future: What to Expect

With WBB’s towering price target of $123, the stakes for CDTX have never been higher. The CD388 platform acts as the central cog, synthesizing expectations of investors and analysts alike. If you imagine every breakthrough as a gust of wind, then CD388 could very well be the sails that drive Cidara towards new horizons.

Providing insight into the broader scope, Cidara’s consistent participation in high-profile investor conferences underscores their readiness to engage with stakeholders and reflect their strategic acumen. Highlighting its proprietary Cloudbreak platform developments, including its lead DFC candidate CD388, is integral to sustaining market interest.

Conclusion

Cidara is standing at the threshold of potential with its CD388 breakthrough seeking to redefine influenza treatment. While a negative net income challenges their path, it’s a calculated effort driven towards transformative research. As anticipation grows for Cidara’s ISRV presentations, traders should remain vigilant, understanding that innovation often demands foresighted perseverance. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.”

Yet, questions linger—How will markets react once the data permeates the wider trader base? Will CD388 become the beacon that changes the landscape for influenza treatment? Only time and diligent observation will reveal the unfolding of Cidara Therapeutics’ visionary pursuits.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”